证券代码：688073 证券简称：毕得医药 公告编号：2025-072 上海毕得医药科技股份有限公司 关于 2025 年半年度计提资产减值准备的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、本次计提减值准备情况概述 根据《企业会计准则》以及上海毕得医药科技股份有限公司（以下简称"公 司"）财务制度等相关规定，为客观公允地反映公司截至 2025 年 6 月 30 日的财 务状况及 2025 年半年度的经营成果，经公司及下属子公司对应收账款、应收票 据、其他应收款、存货、长期股权投资等进行全面充分的评估和分析，认为上述 资产中部分资产存在一定的减值迹象，基于谨慎性原则，公司对相关资产进行了 减值测试并计提了相应的减值准备。2025 年半年度公司计提信用减值损失和资 产减值损失合计 2,191.70 万元，具体情况如下表： 含应收账款、应收票据、其 信用减值损失 -326.94 他应收款 存货跌价损失、长期股权投 资产减值损失 -1,864.76 资减值损失 合计 -2,191.70 — 单位：万元 项目 备注 （损 ...

证券代码：600769 证券简称：祥龙电业 公告编号：2025-025 | 项目 2025 | 年半年度计提（转回）金额 | | --- | --- | | 信用减值损失（损失以"－"号填列） | 9,952,695.51 | | 应收账款信用减值损失 | 10,055,788.01 | | 其他应收款信用减值损失 | -103,092.50 | | 资产减值损失（损失以"－"号填列） | -3,869,396.70 | | 合同资产减值损失 | -3,869,396.70 | | 合计 | 6,083,298.81 | 二、计提及转回资产减值准备的具体情况 （一）信用减值损失 公司以预期信用损失为基础，对应收账款、其他应收款进行减值 测试并确认减值损失。经测试，公司 2025 年半年度共计转回信用减 值损失金额 9,952,695.51 元。 （二）资产减值损失 武汉祥龙电业股份有限公司 关于计提及转回资产减值准备的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 武汉祥龙电业股份有限公司（以下简称"公司"）于 2025 ...

Core Viewpoint - The company has announced the provision for asset impairment totaling 15,662,010.28 yuan, which will reduce its profit for the first half of 2025 [2][4]. Summary by Category Asset Impairment Provision Overview - The company has made provisions for various asset impairments, including: - Inventory impairment provision: 7,782,369.03 yuan - Biological asset impairment provision: 5,238,458.80 yuan - Fixed asset impairment provision: 1,344,922.11 yuan - Bad debt provision: 1,296,260.34 yuan - Total impairment provision: 15,662,010.28 yuan [2][3]. Reasons for Impairment Provisions - **Inventory Impairment**: Due to a decline in milk powder prices influenced by the dairy industry environment, the company recognized an inventory impairment of 7,782,369.03 yuan [3]. - **Biological Asset Impairment**: The company identified that the recoverable amount of biological assets was lower than their book value due to market demand changes, leading to a provision of 5,238,458.80 yuan [3]. - **Fixed Asset Impairment**: A comprehensive inspection revealed signs of impairment in fixed assets, particularly due to the suspension of a wastewater treatment facility, resulting in a provision of 1,344,922.11 yuan [3]. - **Bad Debt Provision**: The company estimated bad debt provisions based on the financial status of debtors, leading to a provision of 1,296,260.34 yuan [3]. Impact of Impairment Provisions - The total asset impairment provision will decrease the company's total profit for the first half of 2025 by 15,662,010.28 yuan [4]. Decision-Making Process - The asset impairment provisions were approved through the company's board of directors and supervisory committee meetings, confirming compliance with accounting standards and reflecting the company's financial situation accurately [5].

证券代码：688063 证券简称：派能科技 公告编号：2025-055 关于 2025 年半年度计提资产减值准备的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、计提减值准备的情况概述 根据《企业会计准则》和上海派能能源科技股份有限公司（以下简称"公司"） 会计政策的相关规定，为客观、公允地反映公司截至2025年6月30日的财务状况 和2025年半年度的经营成果，公司及子公司对截至2025年6月30日合并范围内可 能存在减值损失的各项资产进行了评估和分析，本着谨慎性原则，公司对相关资 产进行了减值测试并计提了相应的减值准备。2025年上半年，公司计提各类信用 及资产减值损失合计人民币45,048,366.77元，具体如下： | | | | 单位：人民币 元 | | --- | --- | --- | --- | | 项目 | 2025 | 年半年度计提金额 | 备注 | | | | | 应收票据坏账损失、应收 | | 信用减值损失 | | 25,520,904.82 | 账款坏账损失、其他应收 | | | | | ...

证券代码：002025 证券简称：航天电器 公告编号：2025-54 贵州航天电器股份有限公司 第八届董事会第三次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 贵州航天电器股份有限公司（以下简称"公司"）第八届董事会第三次会议通知于 会议室召开。会议由公司董事长李凌志先生主持，公司应出席董事 9 人，亲自出席董事 集、召开程序符合《公司法》、 《公司章程》的规定，公司监事、高级管理人员、董事会 秘书列席了会议。经与会董事审议，会议形成如下决议： 一、以 9 票同意、0 票反对、0 票弃权的表决结果审议通过《2025 年半年度报告及 本议案已经公司董事会审计委员会审议通过。 公司《2025 年半年度报告摘要》详细内容见 2025 年 8 月 22 日刊登在《证券时报》 《中国证券报》上的公告；《2025 年半年度报告》全文刊登于巨潮资讯网，供全体股东 和投资者查询、阅读。 经中国证监会（证监许可〔2021〕2341 号）核准，2021 年 8 月贵州航天电器股份 有限公司以非公开发行股票方式向 11 名特定投资者发行股票 23,662,256 ...

天下秀数字科技（集团）股份有限公司 证券代码：600556 证券简称：天下秀 公告编号：临 2025-033 天下秀数字科技（集团）股份有限公司（以下简称"公司"）于2025年8月21 日召开了第十一届董事会第十五次会议和第十一届监事会第十五次会议，审议 通过了《关于公司2025年半年度计提资产减值准备的议案》，现将本次计提减 值准备的具体情况公告如下： 一、本次计提资产减值准备情况概述 根据《企业会计准则》和公司财务管理制度的相关规定，为更加真实、准 确地反映公司 2025 年 6 月 30 日的财务状况以及 2025 年半年度经营成果，公司 及合并范围内子公司基于谨慎性原则，对各类资产进行了清查、分析和评估， 对部分可能发生信用及资产减值的资产计提了减值准备，具体情况如下： 关于公司 2025 年半年度计提资产减值准备的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 单位：人民币万元 项 目 2025年1-6月计提减值准备金额 应收账款坏账损失 705.45 信用减值损失 其他应收款坏账损失 142.17 合 计 8 ...

Core Points - The document outlines the asset impairment management system of Shandong Haihua Co., Ltd, aiming to enhance financial management and mitigate asset loss risks [1] - The system applies to the company and its subsidiaries, covering various asset types including financial assets, inventory, and long-term assets [2] Financial Asset Impairment - The company recognizes impairment losses for financial assets based on expected credit losses [2] - Expected credit losses are calculated as the present value of cash flow shortfalls, weighted by the risk of default [2][3] - Financial instruments are categorized into three stages based on credit risk changes, affecting the measurement of expected credit losses [3][4] Inventory Impairment - Inventory is measured at the lower of cost and net realizable value, with provisions made when costs exceed realizable values [6] - The net realizable value is determined based on estimated selling prices minus estimated costs and taxes [7] Long-term Asset Impairment - Long-term equity investments are assessed for impairment when their recoverable amount is less than their carrying value [7] - The recoverable amount is determined as the higher of fair value less costs to sell and the present value of expected future cash flows [8] Impairment Testing Procedures - The company conducts annual assessments of asset impairment, requiring detailed reports on any identified impairment indicators [10] - The financial center verifies the recoverable amounts and proposes impairment provisions for approval [10] Disclosure Requirements - The company must disclose impairment provisions or write-offs in accordance with relevant laws and regulations [17]

Core Points - The company held its 27th meeting of the 4th Board of Directors on August 19, 2025, where several important resolutions were passed [1] - The board approved the proposal for asset impairment provision [2] - The board also approved the 2025 semi-annual report and its summary [2] - A proposal to cancel the supervisory board was passed, pending approval from the first extraordinary general meeting of 2025 [3] - Multiple amendments to the company's articles of association and various management rules were approved, all pending shareholder approval [4][5] - The board approved an increase in the bank's comprehensive credit limit and guarantees for subsidiaries [5] - A proposal to convene the first extraordinary general meeting of 2025 was also approved [5] Summary by Category Board Meeting Details - The meeting was convened by Chairman Mei Xuhui and attended by all 9 directors, with some represented by proxies [1] - The meeting's procedures complied with relevant laws and regulations [1] Financial Proposals - The board unanimously approved the asset impairment provision with a vote of 9 in favor [2] - The 2025 semi-annual report and its summary were also approved [2] Governance Changes - The proposal to cancel the supervisory board received unanimous approval and will be submitted for shareholder vote [3] - Amendments to the company's articles of association and various governance rules were approved, pending shareholder approval [4][5] Financial Management - The board approved an increase in the bank's comprehensive credit limit and guarantees for subsidiaries, with unanimous support [5] Upcoming Meetings - The board approved the proposal to convene the first extraordinary general meeting of 2025 [5]

Core Viewpoint - The company has approved the provision for asset impairment totaling 12,512,855.34 yuan for the first half of 2025, reflecting a cautious approach to financial reporting and asset valuation [1][3][4]. Summary by Sections Overview of Asset Impairment Provision - The company conducted a comprehensive review and impairment testing of its assets as of June 30, 2025, identifying certain assets with impairment signs and decided to make provisions accordingly [1][3]. Details of Asset Impairment Provision - The breakdown of the asset impairment provision is as follows: - Inventory impairment provision: 7,362,489.31 yuan - Bad debt provision for notes receivable: -2,314,440.49 yuan - Bad debt provision for accounts receivable: 7,203,519.75 yuan - Bad debt provision for other receivables: 261,286.77 yuan - Total: 12,512,855.34 yuan [1][2][3]. Impact on Financial Position - The total provision for asset impairment will reduce the company's profit before tax by 12,512,855.34 yuan for the first half of 2025, thereby affecting the overall financial performance [3][4]. Opinions from Audit Committee - The audit committee agrees that the provision for asset impairment is in line with the company's actual situation and complies with accounting standards, which will provide a more accurate reflection of the company's financial status [3][4]. Opinions from Supervisory Committee - The supervisory committee has reviewed the decision and confirmed that the provision for asset impairment aligns with the company's actual circumstances and relevant regulations, supporting the decision made by the board [4].

Core Viewpoint - The company has released its 2025 semi-annual report, detailing its financial performance and management of raised funds, while ensuring compliance with relevant regulations and transparency in operations [1][5][20]. Group 1: Company Overview - Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. is engaged in the development and production of vaccines and biological products [2]. - The company has not experienced any changes in its controlling shareholder or actual controller during the reporting period [2]. Group 2: Financial Data - The total amount raised from a non-public offering in June 2022 was approximately RMB 349,999.99 million, with a net amount of RMB 346,015.57 million after deducting related expenses [20]. - As of June 30, 2025, the remaining balance of raised funds was RMB 150,940.25 million, including RMB 23,025.20 million in dedicated accounts and RMB 127,915.05 million in principal-protected financial products [21][22]. Group 3: Fund Management - The company has established a dedicated fund management system, ensuring that raised funds are stored in special accounts and managed in compliance with regulations [23][24]. - The company has signed tripartite supervision agreements with banks and its sponsor to ensure the proper use of raised funds [24][25]. Group 4: Fund Utilization - In the first half of 2025, the company directly invested RMB 19,132.35 million into projects funded by the raised capital [21]. - The company has not terminated any new fundraising investment projects during the reporting period [30]. Group 5: Impairment Provisions - The company has recognized a total impairment provision of RMB 8,085.62 million for the first half of 2025, which includes credit impairment losses of RMB 5,743 million and inventory impairment losses of RMB 2,342.62 million [42][44]. - The increase in credit impairment losses is attributed to delayed payments from local disease control centers due to financial constraints [41]. Group 6: Investor Communication - The company plans to hold a semi-annual performance briefing on September 2, 2025, to address investor inquiries and provide insights into its financial results [35][36].